VistaGen Therapeutics Inc

NASDAQ:VTGN   4:00:00 PM EDT
5.28
+0.71 (+15.54%)
7:59:59 PM EDT: $5.55 +0.27 (+5.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)142.70M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.41 Million
Adjusted EPS-$0.36
See more estimates
10-Day MA$4.48
50-Day MA$4.71
200-Day MA$4.18
See more pivots

VistaGen Therapeutics Inc Stock, NASDAQ:VTGN

343 Allerton Avenue, South San Francisco, California 94080
United States of America
Phone: +1.650.577.3600
Number of Employees: 33

Description

VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.